Literature DB >> 19470288

Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications.

Jillan Cantor Sackett1, Ronald A Weller, Elizabeth B Weller.   

Abstract

This paper reviews the risks and benefits of using selective serotonin reuptake inhibitors (SSRIs) in pregnant women. The effects of SSRI use on pregnant women and fetuses are discussed, and the need for SSRI treatment is explained. Persistent pulmonary hypertension of the newborn, teratogenic risks of SSRI treatment during pregnancy, neonatal adaptations, and long-term outcomes for children whose mothers used SSRIs during pregnancy are specifically considered. Due to conflicting results from current studies, there are no clear guidelines for SSRI treatment in pregnancy. Patients and doctors must discuss together the risks and benefits of SSRI use during pregnancy and decide on a course of treatment. Potential risks must be balanced against the effects of untreated maternal depression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470288     DOI: 10.1007/s11920-009-0038-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  38 in total

1.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

Authors:  Carol Louik; Angela E Lin; Martha M Werler; Sonia Hernández-Díaz; Allen A Mitchell
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

Review 2.  The prevalence and impact of alcohol problems in major depression: a systematic review.

Authors:  Lynn E Sullivan; David A Fiellin; Patrick G O'Connor
Journal:  Am J Med       Date:  2005-04       Impact factor: 4.965

Review 3.  Perinatal risks of untreated depression during pregnancy.

Authors:  Lori Bonari; Natasha Pinto; Eric Ahn; Adrienne Einarson; Meir Steiner; Gideon Koren
Journal:  Can J Psychiatry       Date:  2004-11       Impact factor: 4.356

4.  ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy.

Authors: 
Journal:  Obstet Gynecol       Date:  2006-12       Impact factor: 7.661

5.  Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Authors:  Tim F Oberlander; Shaila Misri; Colleen E Fitzgerald; Xanthoula Kostaras; Dan Rurak; Wayne Riggs
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

Review 6.  The spectrum of behaviors influenced by serotonin.

Authors:  I Lucki
Journal:  Biol Psychiatry       Date:  1998-08-01       Impact factor: 13.382

7.  Phototherapy in nonseasonal depression.

Authors:  A Mackert; H P Volz; R D Stieglitz; B Müller-Oerlinghausen
Journal:  Biol Psychiatry       Date:  1991-08-01       Impact factor: 13.382

Review 8.  Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment.

Authors:  Michael J Ostacher
Journal:  Psychiatr Clin North Am       Date:  2007-03

9.  Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

Authors:  Christina D Chambers; Sonia Hernandez-Diaz; Linda J Van Marter; Martha M Werler; Carol Louik; Kenneth Lyons Jones; Allen A Mitchell
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  Birth outcomes after prenatal exposure to antidepressant medication.

Authors:  Victoria Hendrick; Lynne M Smith; Rita Suri; Sun Hwang; Desiree Haynes; Lori Altshuler
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

View more
  3 in total

1.  Affect Expression and Self-Regulation Capacities of Infants Exposed in utero to Psychotropics.

Authors:  Pratibha N Reebye; Tammy W C Ng; Shaila Misri; Irena Stikarovska
Journal:  Front Psychiatry       Date:  2012-02-28       Impact factor: 4.157

Review 2.  Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges.

Authors:  Richard A Epstein; Katherine M Moore; William V Bobo
Journal:  Drug Healthc Patient Saf       Date:  2014-09-18

Review 3.  Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.

Authors:  Katheleen J Gardiner
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.